Mill, Christopher P. http://orcid.org/0000-0003-0957-6009
Fiskus, Warren C. http://orcid.org/0000-0002-7343-6214
DiNardo, Courtney D. http://orcid.org/0000-0001-9003-0390
Reville, Patrick http://orcid.org/0000-0001-8433-3360
Davis, John A.
Birdwell, Christine E.
Das, Kaberi
Hou, Hanxi
Takahashi, Koichi http://orcid.org/0000-0002-8027-9659
Flores, Lauren
Ruan, Xinjia
Su, Xiaoping
Loghavi, Sanam http://orcid.org/0000-0001-8980-3202
Khoury, Joseph D. http://orcid.org/0000-0003-2621-3584
Bhalla, Kapil N. http://orcid.org/0000-0001-5209-5126
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA255721)
Article History
Received: 27 October 2023
Revised: 3 January 2024
Accepted: 5 January 2024
First Online: 5 February 2024
Competing interests
: K.N.B. has received research funding from Iterion, Foghorn and Nurix Pharmaceuticals, and he serves as a consultant for Iterion Therapeutics, none of which are directly related to the content of this paper. All other authors declare they have no conflict of interests to disclose.